


Integrating Genomics and Transcriptomics to reshape Precision Oncology: a *WIN*ning strategy



JUNE 21-22, 2020
BARCELONA, SPAIN






Program

SUNDAY 21 JUNE, 2020

	Welcome and Opening Remarks	Richard L. Schilsky	Chairman WIN Consortium, Villejuif, France American Society of Clinical Oncology (ASCO), Alexandria, USA
		Josep Tabernero	Vice-Chairman WIN Consortium, Villejuif, France Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain


PRESIDENTIAL SESSION 1:

BEYOND DNA TESTING: PLACE OF TRANSCRIPTOMICS IN PRECISION ONCOLOGY

	Opening Keynote Lecture: Expression profiling to discover molecularly and clinically distinct cancer subtypes and to predict response to therapy	Louis M. Staudt	National Cancer Institute (NCI), Bethesda, USA
	Proteomics in Precision Oncology	Gordon B. Mills	Knight Cancer Institute, Oregon Health & Science University (OHSU), Portland, USA
	Keynote Lecture: Functional genomics to identify cancer vulnerabilities	René Bernards	Netherlands Cancer Institute (NKI), Amsterdam, Netherlands
	Molecular profiling of pediatric cancers	Elaine R. Mardis	Nationwide Children's Hospital, Columbus, USA
	Harnessing a synthetic lethality analysis for patient stratification: WINTHER trial	Eytan Rupp	National Institute of Health (NIH), Bethesda, USA

SESSION 2:

NOVEL ALGORITHMS AND DATA VISUALIZATION STRATEGIES TO INTEGRATE GENOMICS AND TRANSCRIPTOMICS

	SIMS algorithm and Digital Display	Vladimir Lazar	WIN Consortium, Villejuif, France
	Molecular artificial intelligence to predict patient treatment response	David Spetzler	Caris Life Sciences, Irving, USA
	RNAseq: technological shift enabling efficient transcriptomics	Kevin White	Tempus, Chicago, USA



Integrating Genomics and Transcriptomics to reshape Precision Oncology: a *WIN*ning strategy

Program

MONDAY 22 JUNE, 2020






SESSION 3:

DISRUPTIVE CONCEPTS AND METHODOLOGICAL INNOVATIONS IN PRECISION ONCOLOGY

	Keynote Lecture Computational tools for patients stratification	Shawn N. Murphy	Harvard Partners, Boston, USA
	Keynote Lecture Consensus molecular subtypes in colon cancer and implications for therapy selection	Sabine Tejpar	University of Leuven, Belgium
	IO in combination: the SPRING trial tri-therapy approach	Benjamin M. Solomon	WIN Consortium, Villejuif, France Avera Cancer Institute, Sioux Falls, USA






SESSION 4:

PREDICTIVE BIOMARKERS TO GUIDE THERAPY SELECTION

	Keynote Lecture TAPUR and derived trials (DRUP, CAPTUR, MOST)	Richard L. Schilsky	American Society of Clinical Oncology (ASCO), Alexandria, USA
	Predictive biomarkers for immune checkpoint inhibitor treatment	Jean-Charles Soria	Gustave Roussy, Villejuif, France
	Biomarker challenges and PanOncology Study concept	Stefan Scherer	GlaxoSmithKline (GSK), Philadelphia, USA
	Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: comprehensive tumor genomic and transcriptomic analyses	Jean-François Martini	Pfizer Inc., La Jolla, USA
	I-PREDICT: first study of personalized combination therapy	Razelle Kurzrock	University of California San Diego, USA

SESSION 5:

NEW CONCEPTS AND THERAPEUTIC APPROACHES IN PRECISION ONCOLOGY ACROSS THE GLOBE: WIN MEMBERS

	Keynote Lecture Early stage lung cancer: challenge and opportunity	Haiquan Chen	Fudan University Shanghai Cancer Center (FUSCC), China
	Integration of T-cell therapy in Precision Oncology clinical trials	Apostolia M. Tsimberidou	The University of Texas MD Anderson Cancer Center, Houston, USA
	Challenges and prospects of precision medicine in the community oncology setting	Rodrigo Dienstmann	Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
	Use of transcriptomics (RNASeq) in the clinic	Tobias Meissner	Avera Cancer Institute, Sioux Falls, USA
	Expanding Precision Oncology across tumor types: advances in prostate cancer	Joaquín Mateo	Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Integrating Genomics and Transcriptomics to reshape Precision Oncology: a *WIN*ning strategy

Program

MONDAY 22 JUNE, 2020

SESSION 6:
BEST POSTERS' AWARD

Best 2 Posters Presentations and Awards



Conclusions

Richard L. Schilsky

Chairman WIN Consortium,
Villejuif, France
American Society of Clinical
Oncology (ASCO), Alexandria, USA



Josep Tabernero

Vice-Chairman WIN Consortium,
Villejuif, France
Vall d'Hebron Institute of Oncology
(VHIO), Barcelona, Spain.